Benefits
Blood pressure reduction
In a 2025 systematic review and meta-analysis of 38 randomised trials and 2,709 adults, a median dose of 365 mg/day of elemental magnesium over a median of 12 weeks lowered systolic blood pressure by 2.81 mmHg and diastolic by 2.05 mmHg compared with placebo. The effect was concentrated in the people who needed it. In adults with high blood pressure already taking medication the drop was 7.68 mmHg systolic and 2.96 diastolic, and in people with low blood magnesium it was 5.97 systolic and 4.75 diastolic. There was no significant effect in people whose blood pressure was already normal. In plain terms, magnesium lowers blood pressure in people with high blood pressure or a low magnesium level, not in people who are already fine. High blood pressure is a medical condition, so anyone on blood pressure medication should talk to their doctor before adding magnesium.
Migraine prevention
Magnesium has been studied in people who already get migraines. In a 1996 randomised, double blind, placebo controlled trial in 81 people with migraine, trimagnesium dicitrate 600 mg/day for 12 weeks reduced attack frequency by 41.6% versus 15.8% on placebo. Attack severity and intensity did not improve significantly, and side effects were common: 18.6% of the magnesium group had diarrhoea and 4.7% had stomach irritation. The American Academy of Neurology guideline that rated magnesium Level B was retired by the AAN Board in September 2015 and can no longer be cited as current guidance; to be fair to magnesium, it was withdrawn over liver safety concerns about butterbur, another ingredient it covered, not because magnesium was found ineffective. Migraine is a medical condition and a supplement is not a treatment for it. The 600 mg/day used in that trial is also well above the 350 mg/day upper limit for supplements, so this is a conversation for your doctor.
Sleep onset latency in older adults
A pooled analysis of just 3 randomised trials in 151 older adults with insomnia found magnesium shortened the time taken to fall asleep by 17.36 minutes versus placebo (95% CI -27.27 to -7.44 minutes). Total sleep time was 16.06 minutes longer, which was not statistically significant, so people fell asleep sooner without clearly sleeping longer. The review authors graded the evidence quality as low because the included trials were at moderate to high risk of bias. This is a small evidence base in older adults with diagnosed insomnia, and no cited trial compared one magnesium form against another.
Magnesium's role in muscle (background biology, not tested in the cited studies)
Magnesium is essential for muscle contraction-relaxation cycling — it competes with calcium at neuromuscular junctions and is the catalytic cofactor for ATP-dependent muscle energy reactions. None of the studies cited on this page measured muscle strength, cramps, soreness or recovery, so there is no clinical evidence here that extra magnesium reduces cramps or improves endurance in people who are not deficient. What magnesium does inside a muscle cell is textbook physiology rather than a tested benefit of supplementing.
Dietary magnesium intake and type 2 diabetes risk (observational only)
A meta-analysis of 13 prospective cohort studies following 536,318 people found that those with the highest dietary magnesium intake had about a 22% lower risk of developing type 2 diabetes (relative risk 0.78). These are observational studies of what people eat, so they show an association and cannot show that taking a magnesium supplement changes anyone's risk. Diets high in magnesium are also high in whole grains, nuts and vegetables, which makes magnesium's own contribution hard to isolate. No supplement trial measuring blood sugar, fasting glucose or insulin resistance is cited on this page, so the claim that supplementing improves those markers is not backed here. Magnesium's role in insulin signalling is a plausible mechanism, not a demonstrated effect, and type 2 diabetes is a medical condition.
Magnesium's role in bone (background biology, not tested in the cited studies)
Magnesium supports calcium absorption, vitamin D activation (cofactor for both 25- and 1α-hydroxylation), and bone matrix formation. About 60% of body magnesium is stored in bone. No study cited on this page measured bone density, bone turnover or fracture rates, so there is nothing here showing that a magnesium supplement changes bone health in either direction. What is described above is background biology. Osteoporosis is a medical condition, and any decision about supplements for bone belongs with your doctor.
Stress, anxiety, and mood
Magnesium modulates NMDA receptor activity and supports GABAergic neurotransmission — pathways central to stress and anxiety. The human evidence here is thin. An open-label (not blinded) trial in 112 adults with mild to moderate depression found magnesium chloride 248 mg/day lowered self-reported depression scores by 6.0 points and anxiety scores by 4.5 points. Because nobody was blinded and both measures are self-reported questionnaires, that design tends to overstate benefit. In the L-threonate cognition trial, effects on anxiety and sleep could not be determined at all, because the placebo group improved so strongly. The one remaining stress and anxiety reference is a study of the branded ingredient Magtein published in EC Nutrition, a journal that is not indexed in PubMed and whose publisher appears on Beall's list of predatory publishers, so it cannot be checked the way every other reference on this page can. Depression and anxiety are medical conditions and magnesium is not a treatment for them.
Cognitive function (one small trial of the L-threonate form)
Magnesium L-threonate (sold as Magtein) was developed because most magnesium forms reach the brain poorly. One randomised, double blind, placebo controlled trial tested it for 12 weeks in 44 adults aged 50 to 70 who already had cognitive impairment. Cognitive scores improved versus placebo (p=0.003, a large effect size of 0.91), but effects on sleep and anxiety could not be determined because the placebo group improved strongly too. Forty-four people in a single unreplicated trial is a small evidence base, the participants were not healthy adults, and results for this one branded form do not carry over to magnesium in general.
Magnesium and sweat losses (background biology, not tested in the cited studies)
Magnesium is one of the four major electrolytes lost through sweat alongside sodium, potassium, and chloride. It's the cofactor for the Na⁺/K⁺-ATPase pump that drives cellular fluid balance. Sports drinks often include 50 to 100 mg per serving. None of the studies cited on this page measured hydration, sweat losses, electrolyte status or exercise performance, so this section describes background biology rather than evidence that a magnesium supplement improves hydration.
Mechanism of action
Cofactor for 300+ enzymatic reactions
Magnesium is a cofactor for over 300 enzymes including those involved in ATP synthesis, DNA replication, protein synthesis, and glucose metabolism. ATP itself exists predominantly as the Mg-ATP complex in cellular metabolism.
Calcium channel modulation
Acts as a natural calcium channel blocker, regulating calcium influx into smooth muscle cells. This is the proposed explanation for the blood pressure effect seen in trials, and the reason magnesium has been investigated in migraine and muscle relaxation. It is a mechanism, not proof that those effects occur.
NMDA receptor regulation and GABA modulation
Magnesium blocks NMDA receptor channels at resting membrane potential, preventing excessive glutamate excitotoxicity. Also modulates GABA-A receptors. These pathways are the usual explanation offered for effects on sleep, anxiety and migraine, but the human results are mixed: the anxiety findings in the cited trials were either open-label or could not be determined at all.
Vitamin D activation
Required cofactor for both 25-hydroxylase (liver) and 1α-hydroxylase (kidney) — the enzymes that convert vitamin D to its active form. Magnesium deficiency limits vitamin D efficacy regardless of intake.
Insulin signaling and glucose metabolism
Magnesium phosphorylates the insulin receptor, supports GLUT4 glucose transporter function, and is required for glucokinase activity. Chronic magnesium deficiency impairs insulin sensitivity and contributes to T2D risk.
Clinical trials
Systematic review and meta-analysis of 38 randomised controlled trials of oral magnesium supplementation for blood pressure. Trials included various magnesium salts (citrate, oxide, chloride, lactate, others). Median intervention 12 weeks. Published in Hypertension.
2,709 participants across 38 clinical trials (hypertensive and normotensive adults). 12-week median intervention.
Median dose 365 mg elemental magnesium per day reduced systolic blood pressure by 2.81 mmHg and diastolic by 2.05 mmHg vs placebo. The effect was concentrated in specific groups: people with high blood pressure already on medication (systolic -7.68, diastolic -2.96 mmHg) and people with low blood magnesium (systolic -5.97, diastolic -4.75 mmHg). There was no significant effect in groups with normal blood pressure.
Evidence review and pooled analysis of randomized controlled trials evaluating oral magnesium supplementation for sleep quality in older adults with insomnia. Published in BMC Complementary Medicine and Therapies. Trials used various magnesium forms; outcomes assessed by validated sleep questionnaires (PSQI, ISI) and actigraphy.
151 older adults with insomnia across 3 clinical trials. 4-8 week supplementation periods.
Magnesium supplementation reduced sleep onset latency by 17.36 minutes vs placebo (95% CI -27.27 to -7.44). Total sleep time was 16.06 minutes longer, which was not statistically significant. Evidence quality graded low due to moderate-to-high risk of bias in included trials, but effect direction is consistent with the mechanistic plausibility.
Randomized double-blind placebo-controlled trial of magnesium L-threonate (Magtein®) for cognitive function in adults aged 50-70 with subjective cognitive impairment. Cognitive function assessed via a battery measuring executive function, memory, attention, and processing speed.
44 adults aged 50 to 70 who already had cognitive impairment. 12-week supplementation.
Magnesium L-threonate improved cognitive scores versus placebo (p=0.003, effect size 0.91). Effects on sleep and anxiety could not be determined, because the placebo group also improved strongly. This is a single trial in 44 people who already had cognitive impairment, it has not been replicated, and its results should not be read as what magnesium does for a healthy adult.
Randomized double-blind placebo-controlled trial of high-dose magnesium for migraine prevention. Used trimagnesium dicitrate at high oral dose for 12 weeks. Outcomes: migraine attack frequency, intensity, duration, and medication use. Published in 1996. It is the trial behind the AAN Level B rating, a guideline that was retired in 2015.
81 patients with episodic migraine (without aura). 12-week intervention.
Trimagnesium dicitrate 600 mg/day reduced migraine attack frequency by 41.6% versus 15.8% with placebo. Attack severity and intensity did not improve significantly. Side effects were common: diarrhoea in 18.6% of the magnesium group and gastric irritation in 4.7%. The American Academy of Neurology guideline that gave magnesium a Level B rating on the strength of trials like this was retired by the AAN Board in September 2015 and is no longer current guidance, although it was withdrawn over safety concerns about butterbur rather than any negative finding about magnesium.
Open-label randomized controlled trial of magnesium chloride for mild-to-moderate depression in adults. Outcomes assessed via PHQ-9 (depression) and GAD-7 (anxiety) validated scales. 6-week intervention period with crossover design.
112 adults with mild to moderate depression. 6-week intervention, open-label, so participants knew they were taking magnesium.
Magnesium chloride at 248 mg/day was followed by a 6.0 point drop in PHQ-9 depression scores and a 4.5 point drop in GAD-7 anxiety scores. The trial was open-label, meaning nobody was blinded, and both outcomes are self-reported questionnaires. That combination tends to inflate apparent benefit, so this is suggestive rather than proof. It was measured in people diagnosed with depression, not in healthy adults.
Randomized placebo-controlled trial of magnesium L-threonate (Magtein®) for sleep quality. Outcomes measured by both objective methods (actigraphy — wrist-worn movement sensors) and subjective methods (Pittsburgh Sleep Quality Index, or PSQI).
80 adults with self-reported sleep problems. 21 days of supplementation.
Magnesium L-threonate at 1 g/day for 21 days improved sleep and self-reported daytime functioning versus placebo in a randomised, double blind, placebo controlled design. This tested one branded form for three weeks in 80 people. No cited study compared it against glycinate or any other form, so any claim that one form beats another for sleep is not supported here.